NCT07784296

Brief Summary

A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,500

participants targeted

Target at P75+ for all trials

Timeline
23mo left

Started Mar 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Mar 2026Aug 2028

Study Start

First participant enrolled

March 19, 2026

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 28, 2026

Completed
28 days until next milestone

First Posted

Study publicly available on registry

August 25, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2028

Last Updated

August 25, 2026

Status Verified

August 1, 2026

Enrollment Period

2.5 years

First QC Date

July 28, 2026

Last Update Submit

August 20, 2026

Conditions

Hypertension

Outcome Measures

Primary Outcomes (1)

  • The change in Systolic Blood Pressure (SBP) relative to baseline

    the 6-month time

Secondary Outcomes (3)

  • effectiveness of sequential triple combination therapy (amlodipine/losartan/chlorthalidone)

    2, 4, 6 months

  • Prescription patterns of a triple-therapy-based stepwise treatment strategy

    2, 4, 6 months

  • safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone)

    2, 4 , 6 months

Interventions

AMOPREL TAB 1.67/16.67/4.17mgDRUG

Follow-up of subjects prescribed medication in a non-intervention study

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

General hospital

You may qualify if:

  • Korean patients aged 19 years or older diagnosed with hypertension
  • Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug
  • Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment
  • Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study

You may not qualify if:

  • Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab.
  • Pregnant women, women who may be pregnant, and nursing mothers
  • Individuals currently participating in an interventional study
  • Individuals deemed unsuitable for participation in this study by the researcher for other reasons

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yongin Severance Hospital

Gyeonggi-do, 16995, South Korea

RECRUITING

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2026

First Posted

August 25, 2026

Study Start

March 19, 2026

Primary Completion (Estimated)

August 31, 2028

Study Completion (Estimated)

August 31, 2028

Last Updated

August 25, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations

KR(1)